Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Baofukang suppository for cervical HPV16/18 infection with LSIL/CIN1 or p16-negative CIN2
ChiCTR2100043957Phase 2Recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baofukang shuan in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Reversal rate of LSIL (CIN1/p16-negative CIN2) at the 7th menstrual cycle and Negative conversion rate of cervical HR-HPV16/18 at the 7th menstrual cycle. Started Feb 2021; status: recruiting.
02
Drugs
baofukang shuan
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on ChiCTR2100043957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043957.